Introduction
Aortic stenosis (AS) is now the most common indication for valve replacement in Europe and North America, with an ever increasing disease prevalence due to the ageing population. 1 The recent introduction of transcatheter aortic valve implantation (TAVI) has renewed interest in the optimal approach to patient management. Decision making in valvular heart disease necessitates a careful evaluation of the risk-to-benefit ratio, considering both the results of intervention and the severity-adjusted risk of adverse outcomes without intervention.
Assessment of aortic stenosis: severity and patient evaluation
The first step in clinical assessment of AS severity is a careful clinical history. Symptoms of AS are typically insidious in onset with most patients initially experiencing decreased exercise tolerance or dyspnoea on exertion. More severe symptoms of AS such as heart failure, angina, and syncope are late manifestations of the disease process. Thus clinicians should specifically ask each patient about current levels of exertion; any change in exercise capacity mandates further evaluation as many patients adjust their lifestyle to avoid symptoms, not realizing they are due to significant valve obstruction. Fatigue may be an equivalent of dyspnoea, breathlessness on exercise may be difficult to interpret in patients with only low physical activity such as the elderly. Finally, symptoms may be due to associated disease such as pulmonary disease, obesity, or de-conditioning. The patient's overall health and comorbidities are also assessed as these are important factors in decision making about the timing and type of intervention. The next step is a comprehensive cardiac physical examination. With severe AS, the classic findings include a delayed and diminished carotid upstroke, a systolic ejection murmur, loudest at the right upper sternal border with radiation to the carotids, and a single S2. However, these findings are not sensitive for diagnosing severe AS, so that echocardiography is appropriate in adults with a loud systolic murmur and in those with cardiac symptoms and any systolic murmur. Echocardiography provides key diagnostic information for risk stratification of adults with AS, including information on valve anatomy and haemodynamics, the left ventricular (LV) response to chronic pressure overload, aortic dilation, and associated valve disease. 2 When transthoracic imaging is suboptimal, transoesophageal, and/or 3D echocardiography may provide better definition of valve anatomy and allow planimetry of valve area. However, anatomic valve area is not identical to physiological valve area (as measured by the continuity equation) and these differences should be considered in clinical decision making. Most outcome studies rely on physiological, not anatomic, orifice area, and this measurement is recommended in current guidelines. 2 -4 Haemodynamic severity of AS is described by three basic parameters: aortic jet velocity, mean transaortic pressure gradient, and valve area. 2 -5 Aortic jet velocity is recorded with continuous wave
Doppler from the window yielding the highest velocity signal, taking care to obtain a parallel intercept angle between the direction of blood flow and the ultrasound beam; underestimation of jet velocity, and thus stenosis severity, is a common error. In smaller adults, valve area should be indexed for body size to avoid a diagnosis of severe AS when obstruction is only moderate. The simple ratio of LV outflow tract to AS velocity also provides a measure of stenosis severity, that is, in effect, indexed for body size. More sophisticated approaches to the evaluation of stenosis severity, such as valvular-vascular impedance provide insights into the complex interactions between valve obstruction, LV load, and the systemic vasculature, but these measures are not recommended in routine clinical practice. 2 Left ventricular size and systolic function are evaluated qualitatively on 2D or 3D imaging. In addition, quantitative measures of LV ejection fraction and ventricular volumes are measured based on tracing endocardial borders at end-diastole and end-systole. Typically, LV systolic function remains normal until late in the disease course but some adults with AS have LV systolic dysfunction concurrent with or just before symptom onset. However, LV diastolic dysfunction is common even early in the disease course, particularly in older women with AS, and can be evaluated using Doppler parameters of diastolic dysfunction.
Guidelines consistently state that the general rule for quantifying the severity of valvular disease is to combine and check for the consistency of different indices and to be aware of potential errors of measurements. AS severity is categorized as mild, moderate, or severe (Table 1) . However, these categories of AS severity only provide a frame of reference-each of these measurements is a continuous variable; symptom onset does not occur at specific numerical value; patients may have an AS velocity, pressure gradient, and valve area that do not all fit in the same category; these categories do not consider coexisting aortic regurgitation or LV dysfunction; and all these parameters vary with physiological changes, such as high or low cardiac output states, and changes in blood pressure or heart rate. The clinical value of measuring AS severity is to ensure that valve obstruction is the cause of the patient's symptoms or to predict clinical prognosis.
Additional diagnostic imaging is helpful in selected patients. When coronary artery disease is suspected, coronary angiography is recommended. Computed tomography (CT) coronary angiography may be reasonable in younger patients but is not adequate in older patients 3, 4 due to the high prevalence of CAD. In patients with a bicuspid aortic valve further evaluation of aortic anatomy and size by CT or cardiac magnetic resonance may be helpful.
Consequences and assessment of spontaneous risk
Calcific AS is a progressive disease with a spectrum ranging from mild aortic valve thickening without obstruction to LV outflow, termed aortic valve sclerosis, to severe valve obstruction requiring surgical intervention. 6 Aortic sclerosis is present in 25% of adults over 65 years of age; however, only about 10% of these patients progress to haemodynamically significant AS. 7 The presence of calcific valve disease is associated with older age, male gender, elevated serum lipoprotein levels, diabetes, smoking, metabolic syndrome, and hypertension. 8, 9 In contrast, progression from sclerosis to stenosis has only been associated with age and male gender, but not serum C-reactive protein levels, in studies to date. 7 However, once even mild obstruction is present, further valve narrowing appears inevitable in most patients. The average rate of haemodynamic progression is an increase in mean transaortic gradient of 7 mmHg/year, an increase in velocity of 0.3 m/s/year and a decrease in valve area of 0.1 cm 2 /year, although there is wide individual variability. 10 The strongest predictor of clinical outcome in adults with AS is severity of valve obstruction. 3 and American College of Cardiology/American Heart Association (ACC/ AHA) Valve Guidelines. 4 ACC/AHA guidelines use lower mean gradient cutoffs as indicated in parentheses. The ESC definitions apply only in the presence of normal flow conditions. The velocity ratio is included in the ASE/EAE guidelines only.
under the supervision of an experienced physician who should stop the test for any symptoms or if blood pressure fails to rise appropriately.
Exercise stress echocardiography has been proposed for risk stratification in asymptomatic severe AS.
14 Although the increase in mean pressure gradient with exercise has been reported to predict outcome and provide information beyond a regular exercise test, more data are required to validate this finding and recommend its use in clinical practice. In asymptomatic adults, elevated serum brain natriuretic peptide (BNP) levels are predictive of symptom onset; with symptomatic severe AS, higher BNP levels are associated with a higher operative mortality and suboptimal post-operative outcomes. 15 Most adults with AS have a gradual increase in outflow obstruction, symptoms do not occur until severe obstruction is present, the risk of sudden death in the absence of symptoms is very low (,1%/year), and symptom onset precedes LV dysfunction. The rationale for considering valve surgery in adults with asymptomatic severe AS revolves around the risk of surgery, the risk of the valve prosthesis, and the rate of haemodynamic progression. Reliable clinical predictors for the rate of progression have not yet been defined. However, serial studies allow assessment of the rate of progression in individual patients and factors such as valve anatomy (rheumatic, bicuspid, or trileaflet), the degree of valve calcification, exercise testing, and serum BNP levels are helpful in clinical decision making.
Although symptom onset and AS severity easily define the timing of intervention in most adults with AS, there are some difficult clinical situations. For example, some patients have symptoms with what appears to be only moderate stenosis. In some cases, these patients have mixed stenosis and regurgitation with a valve area and pressure gradient that would be classified as moderate if only isolated AS were present. Even so, it is important to carefully evaluate for other potential causes of symptoms; if no other cause is identified, it is possible that this degree of AS is significant for this patient. 5 Hypertension is common in adults with AS. Hypertension both confounds the evaluation of AS severity and imposes a double-load on the LV: increased systemic vascular resistance in addition to valve obstruction. 16 When hypertension is present, stroke volume is reduced, resulting in a lower pressure gradient than expected for the degree of stenosis. In addition, for a given degree of valve obstruction, the higher total LV load in the hypertensive patient results in LV dysfunction and may result in earlier symptom onset. The most practical approach to decision making, when AS severity is uncertain and hypertension is present, is cautious medical therapy with re-assessment of AS severity when the patient is normotensive. Another clinical conundrum is the patient with a small valve area but only a modest pressure gradient. 17, 18 Some of these patients have severe stenosis with a low forward cardiac output due to small ventricular volumes, despite normal systolic function, so that velocity and pressure gradient are relatively low. In these patients with 'paradoxical low-flow AS', valve area may better reflect stenosis severity than velocity or pressure gradient. Conversely, a small valve area in an adult with a small body size may reflect only mild to moderate stenosis. In patients with a small valve area and LV systolic dysfunction, it is challenging to identify which patients have severe AS with a low gradient due to low stroke volume (low-gradient, low-flow AS) vs. those who have only moderate AS. Clinical outcomes are poor in both groups, but those with severe AS benefit from valve replacement. In contrast, those with a primary cardiomyopathy and incidental mild -moderate AS may best be treated with medical therapy. Severe stenosis is confirmed on dobutamine stress echocardiography, if the peak velocity is .4.0 m/s or mean gradient .40 mmHg with a valve area 1.0 cm 2 at any flow rate. 2, 19 If stroke volume or ejection fraction fails to increase by at least 20% with dobutamine, the patient has 'absence of contractile reserve' and is in a particularly high-risk group. 20 Some studies suggest that Doppler derived LV strain and strain rate are predictive of recovery of LV function after relief of AS. 21 Finally, patients with bicuspid valves are exposed to a high risk of cardiac events, which are mainly related to the development of AS, particularly in those with echographic valve degeneration at diagnosis. In addition, the risk of aortic complication is notable. 22 
Evaluation of the risk of surgery
Aortic valve replacement (AVR) is the definitive therapy for severe AS. Over time, operative risk has dramatically decreased, currently operative mortality of isolated AVR is 2-5% in patients ,70 years and 5-15% in older adults, including selected octogenarians or even nonagenarians. If bypass surgery is combined with valve replacement, operative mortality ranges from 5 to 7%. 1,23 -29 Factors associated with an increased operative risk include cardiac-related factors, such as higher functional class, emergency operation, LV dysfunction especially in the absence of contractile reserve, pulmonary hypertension, co-existing coronary disease, atrial fibrillation, previous cardiac surgery, and factors related to demographics (older age, female gender)or to associated comorbidities, in particular COPD, renal insufficiency, and peripheral arteriosclerosis.
After valve replacement, symptoms diminish, quality-of-life improves, and long-term survival is similar to that expected for an age-matched population. 27 Late outcome after AVR depends mainly on the stage of heart disease before surgery, prosthetic related complications, and co-morbidities. Risk factors for poor post-operative outcomes include age (even though survival in the elderly is favourable relative to expected outcomes), comorbidities, severe functional limitation, irreversible myocardial damage such as a large myocardial scar, severe LV hypertrophy, more severe AS, ventricular arrhythmias, and untreated co-existing coronary disease. In addition, poor post-operative outcomes may result from prosthesis-related complications or sub-optimal prosthetic valve haemodynamic performance. 28 Multivariate risk scores 26, 29 are increasingly used to estimate operative mortality based on both cardiac and extra-cardiac factors using either a numerical scoring system or web-based entry of relevant clinical parameters, with risk calculated by a complex algorithm. The Society of Thoracic Surgeons predicted risk of mortality (STS-PROM) score appears to be more reliable than the EuroSCORE for predicting outcomes of high-risk AVR patients, but tends to underestimate mortality. 24 All these scores A. Vahanian and C.M. Otto share similar limitations: predictive ability is reduced in high-risk patients who represented only a small proportion of the population used to derive these scores-high-risk patients form a pathologically heterogeneous group in which it is difficult to capture all comorbidities-with the exception of STS-PROM, 26 the predictive value of these scores for morbidity and long-term results are largely unknown-finally, they do not take into account the surgical results in a given institution, for example, high volume centres have a significantly lower operative risk. In practice, the key element to establish whether patients are at high-risk for surgery is clinical judgment, which should be used in association with a more quantitative assessment based on the combination of several scores, since the population identified as high risk by all algorithms is concordantly at high-risk in all series even if the level of the risk is different. 24, 30 Such an approach allows the team to take into account risk factors that are not covered in scores but often seen in practice such as chest radiation, previous coronary-bypass surgery with patent grafts, porcelain aorta, liver sclerosis, and also a number of demographic variables such as frailty, nutritional status, and debility.
Evaluation of the risk of transcatheter aortic valve implantation
Seven years after the first-in-man TAVI, over 6000 patients have been treated using this method, using either a retrograde femoral or an antegrade trans-apical approach. Patients treated have mostly been elderly, at high-risk or with contra-indications for surgery. The results are preliminary and any conclusions carry inherent limitations. It appears that TAVI is feasible and provides acceptable clinical and haemodynamic results up to 3 years. 30 -32 Owing to the limited amount of data available, it is difficult to identify predictors of risk in TAVI. The immediate risk is mostly related to the experience of centres in performing the technique and to the clinical condition of the patients (in particular clinical comorbidities and LV function). Long-term results are more dependent on comorbidities rather than the cardiac status.
Evaluation of life expectancy
Life expectancy is most significantly influenced by comorbidities, which should be looked for carefully, particularly in the elderly. In addition to clinical evaluation, semi-quantitative scoring systems have been developed that include comorbidities and measures of functional capacity. These scores have good predictive accuracy in the estimation of mortality in different age groups.
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Treatment strategy
Multi-disciplinary assessment is essential for risk-assessment and choice of the treatment strategy. It should involve consultation between cardiologists, surgeons, and anaesthesiologists. Finally, the proposal made by the team should be aligned with the wishes of the patient and their family after appropriate discussion. The practical recommendations for management of patients with severe AS are summarized in Figure 1 . The European Society of Cardiology (ESC) 3 and American College of Cardiology/American Heart Association (ACC/AHA) 4 guidelines for the management of a patient with severe AS are very helpful for the clinician. Both sets of guidelines share many similarities, as summarized in Table 2 . However, these recommendations are primarily based on expert consensus, and most of the recommendations are only level of evidence 'B' or 'C', underlining the knowledge gaps in many areas. On the other hand, in several domains, it is neither appropriate nor necessary to consider randomized prospective trials in all settings such as in the management of severe symptomatic AS where a randomized trial between surgery and medical therapy would be highly inappropriate, because clinical experience strongly supports relief of AS in this situation. Conversely, it is necessary to evaluate new approaches such as TAVI in comparison with current clinical standards, i.e. natural history or surgical AVR. 30 One important step is to educate primary care physicians about the current indications for AVR. Several surveys have shown that 30 -40% of patients with severe symptomatic AS are not referred for surgical consideration due to lack of knowledge of the dismal spontaneous prognosis and misconceptions about surgical risk, 35 particularly for elderly patients where age per se is not a contra-indication to surgery.
3,4
On the basis of current clinical outcomes data, TAVI may be considered in patients with severe AS with symptoms and a life expectancy .1 year when there are definite contraindications to surgery or when surgery is judged very high risk and there are no barriers to TAVI. 30 Indications for balloon aortic valvuloplasty are now very limited, with valvuloplasty primarily considered as a bridge to surgery, or TAVI, in haemodynamically unstable patients. Finally, it seems reasonable to manage medically patients with a very limited life expectancy. 3, 4, 30 Further clinical studies are needed to assess the optimal management of patients with low output AS and low ejection fraction. This group of patients is characterized by high-operative risk but a dismal spontaneous prognosis. In patients with contractile reserve, surgery should be considered. The outcome of patients without contractile reserve is compromised by high-operative mortality. However, survival is better after surgery 20 and surgery can be performed in the absence of severe comorbidities. As an illustration in a series of 85 patients without contractile reserve, in patients who were operated, operative mortality was 22% and 5-year survival was 55% vs. only 14% in medically managed patients. 20 In the group of patients with low forward stroke volume despite a normal ejection fraction, additional diagnostic evaluation is needed and decision making must be individualized. More data are needed before suggesting recommendations. Factors suggesting severe AS include the consideration of valve area indexed for body size ,0.6 cm/m 2 ), the ratio of LV outflow to aortic velocity (,0.25), and the severity of leaflet calcification and an elevated serum BNP level. Aortic valve replacement could be recommended when symptoms are present and if valve calcification suggests significant valve obstruction.
Risk stratification in aortic stenosis Once symptoms occur, intervention is recommended if symptoms are due to severe AS as shown in Table 2 . Evaluation for other causes of symptoms is needed when AS is mild or moderate in severity.
b Interval for repeat CT or CMR depends on severity of aortic enlargement.
Risk stratification in aortic stenosis with the ACC/AHA inclusion of age, severe valve calcification, and coronary disease as predictors of rapid progression. The level of recommendation for surgery according to the results of exercise testing is higher in the ESC guidelines than the ACC/AHA ones. In the ESC guidelines, if the exercise test is abnormal, particularly if it shows symptoms, then there is a strong indication for surgery in a physically active patient. Interestingly, the ACC/AHA guidelines also stress the fact that in patients in whom AVR may be delayed, earlier intervention may be considered with severe asymptomatic AS to account for disparities in access to healthcare and geographical barriers to rapid medical care. Ultimately, we need to discover medical therapies that prevent the development or progression of valvular AS. In the meantime, periodic evaluation of symptoms and disease severity is recommended, along with therapy of standard cardiac risk factors per established guidelines. 36 
Conclusions
Risk stratification and decision making are particularly complex in adults with AS, because the disease mainly affects elderly patients who represent a heterogeneous population and require balanced and individualized analysis using a multidisciplinary collaboration. Further research is needed to provide better evidence in particular on spontaneous risk, earlier detection of LV dysfunction, and the results of transcatheter treatment and medical therapy.
Conflict of interest: none declared.
